In conclusion, the current results highlight gemigliptin add-on therapy as an effective treatment option when compared with metformin dose escalation in patients with T2DM exhibiting inadequate glycemic control using metformin and SGLT2 inhibitors, without safety concerns. Here, SLC5A2 is linked to type 2 diabetes mellitus.